a, Copy number profile of MB-REC-12 therapy-naive (WT, green, left panel) and recurrent tumour (loss, blue, lower panel), showing recurrence-specific loss of chr14q. b, DYNC1H1 expression is reduced in Shh patients with chr14q loss (n = 18/80, Mann–Whitney test, P < 0.0001, centre lines show the medians; box limits indicate the 25th and 75th percentiles; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles). c, Expression of the chr14 signature genes discriminating between chr14q balanced (n = 34) and chr14q loss (n = 18) in the Boston cohort of Shh medulloblastoma samples.